详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Inhibition of Axl improves the targeted therapy against ALK-mutated neuroblastoma.

117| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Department of Neurology, Sichuan Medical Science Institute & Sichuan Provincial Hospital, Chengdu 610072, China [2]Department of Radiotherapy, Shanghai First People’s Hospital, Shanghai Jiao Tong University, Shanghai 201620, China [3]Department of Burn and Plastic Surgery, Huai’an First People’s Hospital, Nanjing Medical University, Huai’an 223300, China

出处：

DOI：

ISSN：

关键词： Neuroblastoma ALK Targeted therapy Axl Small-molecule inhibitor

摘要：

Neuroblastoma (NB) patients harboring mutated ALK can be expected to potentially benefit from targeted therapy based on ALK tyrosine kinase inhibitor (TKI), such as crizotinib and ceritinib. However, the effect of the treatment varies with different individuals, although with the same genic changes. Axl receptor tyrosine kinase is expressed in a variety of human cancers, but little data are reported in NB, particularly in which carrying mutated ALK. In this study, we focus on the roles of Axl in ALK-mutated NB for investigating rational therapeutic strategy. We found that Axl is expressed in ALK-positive NB tissues and cell lines, and could be effectively activated by its ligand GAS6. Ligand-dependent Axl activation obviously rescued crizotinib-mediated suppression of cell proliferation in ALK-mutated NB cells. Genetic inhibition of Axl with specific small interfering RNA markedly increased the sensitivity of cells to ALK-TKIs. Furthermore, a small-molecule inhibitor of Axl significantly enhanced ALK-targeted therapy, as an increased frequency of apoptosis was observed in NB cells co-expressing ALK and Axl. Taken together, our results demonstrated that activation of Axl could lead to insensitivity to ALK inhibitors, and dual inhibition of ALK and Axl might be a potential therapeutic strategy against ALK-mutated NB. Copyright © 2014 Elsevier Inc. All rights reserved.

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2014]版：

大类 | 3 区生物

小类 | 4 区生化与分子生物学 4 区生物物理

最新[2023]版：

大类 | 3 区生物学

小类 | 3 区生物物理 4 区生化与分子生物学

JCR分区：

出版当年[2014]版：

Q3 BIOPHYSICS Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY

最新[2023]版：

Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY Q3 BIOPHYSICS

影响因子： 2.5 最新[2023版] 2.7 最新五年平均 2.297 出版当年[2014版] 2.382 出版当年五年平均 2.281 出版前一年[2013版] 2.371 出版后一年[2015版]

第一作者：

第一作者机构： [1]Department of Neurology, Sichuan Medical Science Institute & Sichuan Provincial Hospital, Chengdu 610072, China

共同第一作者：

通讯作者：

通讯机构： [3]Department of Burn and Plastic Surgery, Huai’an First People’s Hospital, Nanjing Medical University, Huai’an 223300, China [*1]Department of Burn and Plastic Surgery, Huai’an First People’s Hospital, Nanjing Medical University, 6 Beijing Road West, Huai’an 223300, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]A dual MET/AXL small-molecule inhibitor exerts efficacy against gastric carcinoma through killing cancer cells as well as modulating tumor microenvironment. [2]Small-Molecule Inhibitor of 8-Oxoguanine DNA Glycosylase 1 Regulates Inflammatory Responses during Pseudomonas aeruginosa Infection. [3]Discovery of BAZ1A bromodomain inhibitors with the aid of virtual screening and activity evaluation. [4]ALK阳性非小细胞肺癌靶向治疗及其耐药机制的研究进展 [5]Discovery of a novel small-molecule inhibitor of Fam20C that induces apoptosis and inhibits migration in triple negative breast cancer. [6]Inhibition of METTL3 Alleviates NLRP3 Inflammasome Activation via Increasing Ubiquitination of NEK7 [7]Case report: Concomitant EGFR mutation and ALK rearrangement in non-small cell lung cancer [8]EML4-ALK融合基因重排对晚期非小细胞肺癌诊断及治疗价值 [9]Systems biology approaches based discovery of a small molecule inhibitor targeting both c-Met/PARP-1 and inducing cell death in breast cancer [10]AXL